Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Synthesis and Preclinical Evaluation of a 89Zr-labelled Human Single Chain Antibody for Non-invasive Detection of Hepatic Myofibroblasts in Acute Liver Injury

Lookup NU author(s): Dr Toni Pringle, Erik Ramon Gil, Dr Jack LeslieORCiD, Professor Fiona OakleyORCiD, Professor Matthew Wright, Dr James KnightORCiD, Dr Saimir LuliORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Synaptophysin is expressed on fibrogenic hepatic myofibroblasts. C1-3 is a single chain human antibody (scAb) that binds specifically to synaptophysin on hepatic myofibroblasts, providing a targeting vector for novel in vivo imaging agents of chronic liver disease. C1-3 and a negative control scAb, CSBD9, were radiolabelled with zirconium-89 via desferrioxamine chelation to enable non-invasive molecular imaging with Positron Emission Tomography (PET). DFO-scAb conjugates were characterised by gel electrophoresis (SDS-PAGE) and MALDI-TOF spectrometry, and 89Zr-labelled with high radiolabelling efficiency (99%). [89Zr]Zr-DFO-C1-3 exhibited high in vitro stability (>99%) in mouse and human sera over three days at 25 and 37°C. Activated hepatic myofibroblasts incubated with [89Zr]Zr-DFO-C1-3 displayed significantly higher internalised activity (59.46%, P = 0.001) compared to the [89Zr]Zr-DFO-CSBD9 control, indicating synaptophysin-mediated uptake and high binding specificity of [89Zr]Zr-DFO-C1-3. Mice with CCl4-induced acute liver damage exhibited significantly higher liver uptake of [89Zr]Zr-DFO-C1-3, compared to controls, confirmed by both Cerenkov imaging and ex vivo gamma counting (4.41 ± 0.19 %ID/g, P < 0.0001). CCl4-induced liver damage and the number of hepatic myofibroblasts was confirmed by aSMA staining of liver sections. These findings indicate that [89Zr]Zr-DFO-C1-3 has promising utility as a PET imaging agent for non-invasive detection of hepatic myfibroblasts following acute liver injury.


Publication metadata

Author(s): Pringle TA, Ramon-Gil E, Leslie J, Oakley F, Wright MC, Knight JC, Luli S

Publication type: Article

Publication status: Published

Journal: Scientific Reports

Year: 2024

Volume: 14

Online publication date: 05/01/2024

Acceptance date: 25/12/2023

Date deposited: 20/12/2023

ISSN (electronic): 2045-2322

Publisher: Nature Publishing Group

URL: https://doi.org/10.1038/s41598-023-50779-w

DOI: 10.1038/s41598-023-50779-w

Data Access Statement: The datasets generated and material generated in the current study are available from the corresponding author on reasonable request.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
MR/K0019494/1
MRC
MR/R023026/1Medical Research Council (MRC)
Wellcome Trust
WE Harker Foundation

Share